Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shuttle Pharmaceuticals HoldingsSHPH -3.84%24 Equity-to-Asset is 0.28 as of Mar. 2026, which is 28% below its 10-year median of 0.39. GuruFocus rates SHPH with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Shuttle Pharmaceuticals Holdings ranks worse than 84.08% on this metric.
The historical rank and industry rank for Shuttle Pharmaceuticals Holdings's Equity-to-Asset or its related term are showing as below:
SHPH'
s Equity-to-Asset Range Over the Past 10 Years
Min: -13.33 Med: 0.39 Max: 0.9
Current: 0.28
During the past 6 years, the highest Equity to Asset Ratio of Shuttle Pharmaceuticals Holdings was 0.90. The lowest was -13.33. And the median was 0.39.
SHPH's Equity-to-Asset is ranked worse than 84.08% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs SHPH: 0.28
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Shuttle Pharmaceuticals Holdings Equity-to-Asset Related Terms
Shuttle Pharmaceuticals Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHPH vs PLSH, SKYI, CPMD: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shuttle Pharmaceuticals Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Shuttle Pharmaceuticals Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shuttle Pharmaceuticals Holdings (SHPH) has a Equity-to-Asset of 0.28 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. This is 28% below median its historical median of 0.39. According to the industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #845 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 84.1%.
Is Shuttle Pharmaceuticals Holdings' Equity-to-Asset too high?
Shuttle Pharmaceuticals Holdings' current Equity-to-Asset of 0.28 is 28% below median its 10-year median of 0.39. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Shuttle Pharmaceuticals Holdings' value of 0.28 is 54.1% below this industry median. Based on the distribution chart, Shuttle Pharmaceuticals Holdings ranks #845 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' Equity-to-Asset compare to PLSH and SKYI?
According to the Drug Manufacturers industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #845 out of 1005 companies for Equity-to-Asset. This places Shuttle Pharmaceuticals Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Shuttle Pharmaceuticals Holdings' value of 0.28 is 54.1% below this benchmark. While the company's 10-year median is 0.39 vs. the industry median of 0.61, Shuttle Pharmaceuticals Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shuttle Pharmaceuticals Holdings's current Equity-to-Asset of 0.28 is 54.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shuttle Pharmaceuticals Holdings's current Equity-to-Asset is 0.28, which is 28% below median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current Equity-to-Asset of 0.28. The current Equity-to-Asset is 0.28, which is 28% below median its 10-year median of 0.39 and 54.1% below the Drug Manufacturers industry median of 0.61. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current Equity-to-Asset is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score
Get the complete analysis for SHPH
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPH has been successfully added to your 
